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Abstract
Background
The impact of Chlamydia trachomatis (chlamydia) control on the incidence of pelvic inflam-
matory disease (PID) is theoretically limited by the proportion of PID caused by chlamydia.
We estimate the population excess fraction (PEF) of treated chlamydia infection on PID at
12-months in settings with widespread chlamydia control (testing and treatment) and com-
pare this to the estimated PEF of untreated chlamydia.
Methods
We used two large retrospective population-based cohorts of women of reproductive age
from settings with widespread chlamydia control to calculate the PEF of treated chlamydia on
PID at 12-months. We undertook a systematic review to identify further studies that reported
the risk of PID in women who were tested for chlamydia (infected and uninfected). We used
the same method to calculate the PEF in eligible studies then compared all estimates of PEF.
Results
The systematic review identified a single study, a randomised controlled trial of chlamydia
screening (POPI-RCT). In the presence of testing and treatment <10% of PID at 12-months
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was attributable to treated (baseline) chlamydia infections (Manitoba: 8.86%(95%CI 7.15–
10.75); Denmark: 3.84%(3.26–4.45); screened-arm POPI-RCT: 0.99%(0.00–29.06)). In the
absence of active chlamydia treatment 26.44%(11.57–46.32) of PID at 12-months was
attributable to untreated (baseline) chlamydia infections (deferred-arm POPI-RCT). The
PEFs suggest that eradicating baseline chlamydia infections could prevent 484 cases of
PID at 12-months per 100,000 women in the untreated setting and 13–184 cases of PID per
100,000 tested women in the presence of testing and treatment.
Conclusion
Testing and treating chlamydia reduced the PEF of chlamydia on PID by 65% compared to
the untreated setting. But in the presence of testing and treatment over 90% of PID could
not be attributed to a baseline chlamydia infection. More information is needed about the
aetiology of PID to develop effective strategies for improving the reproductive health of
women.
Introduction
Many high-income countries invest heavily in opportunistic testing or screening for Chla-
mydia trachomatis (chlamydia) with the aim of reducing the incidence of infection and post-
infectious complications (including pelvic inflammatory disease (PID)).[1, 2] The strongest
evidence for chlamydia testing comes from a meta-analysis of randomised-controlled trials
(RCT) that demonstrates the benefit of testing young women (under 25 years). For an in-
dividual, the offer of a chlamydia test can reduce her risk of PID at 12-months by 32% (RR
0.68; 95%CI 0.49–0.94).[3] However, it has not yet been shown that widespread testing for
chlamydia can impact on the incidence or prevalence of infection or complications in the
population.
Opportunistic testing and screening are interventions applied at the level of the population.
To estimate the potential population-level health impact requires information about the rela-
tive risk of PID in chlamydia-positive compared to chlamydia-negative women (“relative
risk”) and the prevalence of chlamydia. The resulting parameter is the population excess frac-
tion (PEF)—also known as the “population attributable risk” or “population aetiologic frac-
tion”. It is an estimate of the proportion of PID that could be prevented in a population if a
causal exposure (a positive chlamydia test) was eradicated (or more correctly, if the exposure-
level in those categorised as exposed (chlamydia-positive) was reduced to the level in those cat-
egorised as non-exposed (chlamydia-negative)).
The PEF provides useful information for determining how to invest resources for maximal
health gain. A recent modelling study, that combined data from multiple sources, estimates
that in the absence of chlamydia control interventions 19.7% (95% CI 5.9–38.1) of PID is
attributable to an untreated chlamydia infection.[4] The authors also estimate that the widely
used policy of annual chlamydia testing in young adults can prevent a maximum of 61% of
cases of chlamydia-associated PID.
We aim to estimate the PEF of diagnosed chlamydia on PID at 12-months in women from
the general population who are tested for chlamydia (infected and uninfected) and followed
up (for at least 12-months) for the outcome of PID. This will provide additional information
from a real-world setting that can be used to inform modelling studies and investment in chla-
mydia control interventions.
Population excess fraction of chlamydia on pelvic inflammatory disease
PLOS ONE | DOI:10.1371/journal.pone.0171551 February 15, 2017 2 / 12
corresponding author: bethan.davies06@imperial.
ac.uk.
Funding: BD was funded by an Medical Research
Council Population Health Scientist Fellowship
(G0902120); KT was funded by a National Institute
of Health Research Post-Doctoral Fellowship 2009-
02-055 (Jan 2009 - Dec 2014). This paper presents
independent research funded by the National
Institute for Health Research (NIHR). The views
expressed are those of the author(s) and not
necessarily those of the NHS, the NIHR or the
Department of Health. (Note only KT received direct
funding during the preparation of this paper). The
Wellcome Trust (090285/Z/09/Z) funded H. Ward
and the development and analysis of the MWSRH
cohort; BD and HW received funding from the
National Institute for Health Research (NIHR)
Biomedical Research Centre (BRC) based at
Imperial College Healthcare NHS Trust and
Imperial College London, UK; Unrestricted partial
funding for the Danish Chlamydia Study was
received from Frederiksberg Kommune,
Frederiksberg, Denmark. The funders had no role
in study design, data collection and analysis,
decision to publish, or preparation of the
manuscript.
Competing interests: BD and H. Ward received
personal consultancy fees for the European Centre
for Disease Prevention and Control. H. Westh
received personal fees from Hologic, Novo Nordik
and Illumina and grants from Hologic. KT reports
personal fees from Aquarius Population Health. TB
received personal fees from Abbvie, Bristol Myers
Squibb, Gilead, and GSK and non-financial support
from Bristol Myers Squibb and Gilead. JB, SL, MF
and BNY have nothing to disclose. This does not
alter our adherence to PLOS ONE policies on
sharing data and materials.
Methods
Ethics statement
MWRSH cohort: Institutional approval for use of the administrative healthcare data was
obtained from the Health Information Privacy Committee at Manitoba Health (study approval
number: HIPC 2010/2011-48). Ethical approval for the use of pseudo-anonymized administra-
tive health data was obtained from the Health Research Ethics Board at the University of Mani-
toba. All data were provided and hosted by the Manitoba Centre for Health Policy within the
University of Manitoba. Denmark Chlamydia Study: The study was approved by the Danish
Data Protection Agency (J.nr. 2010-41-4866 and J.nr. 2012-331-0228).
Primary data analysis
We analysed two retrospective population-based cohorts with individual-level linked data on
chlamydia and PID (Manitoba Women’s Reproductive and Sexual Health (MWRSH) cohort
and Denmark Chlamydia Study) that have been described in full elsewhere.[5, 6]
Briefly, the MWRSH cohort is a birth cohort that links demographic information from the
Province of Manitoba’s health insurance system (Manitoba Health Insurance Registry [7]),
chlamydia test data from the Province’s main microbiology laboratory (Cadham Provincial
Laboratory [8]) and healthcare presentations for PID (in-patient, out-patient and community
setting) from the Province’s administrative healthcare datasets (Medical Claims and Hospital
Separations Abstracts [9]) (Table 1). The dataset has complete ascertainment of chlamydia
tests undertaken in public laboratories and diagnosed episodes of PID excluding those seen
only at an Emergency Department. This cohort contains 147,258 female residents of Manitoba
aged 12–24 years in 1992–1996 who were followed-up until 2008. In this analysis, the cohort
was restricted to the 72,883 women who were tested for chlamydia and did not have a PID
diagnosis before their first chlamydia test in the cohort.[6] All women entered the cohort on
the date of their first chlamydia test during the study period. We defined chlamydia prevalence
(pe) as the proportion of women who had a positive result at their first chlamydia test in the
cohort. We classified women according to the result of this first test and determined the pro-
portion of chlamydia-negative (Iu) and chlamydia-positive (Ie) women who had a healthcare
presentation with PID by 12-months.
The Denmark Chlamydia Study links demographic information from the Danish Civil Reg-
istration system,[13] chlamydia test data from a purpose-generated dataset of all chlamydia
tests performed in public laboratories and healthcare presentations for PID (out-patient, emer-
gency department and in-patient) in the Danish National Patient Register.[14] The dataset has
complete ascertainment of chlamydia tests undertaken in public laboratories and diagnosed
episodes of PID seen in secondary care (no primary or community care presentations). The
Denmark Chlamydia Study contains all women in Denmark (including Greenland) with a
positive chlamydia test (1st January 1992 – 2nd November 2011) and four age- and sex-matched
controls who were followed up until 2012 (n = 605,475). A cohort of 516,720 women resident
in Denmark who entered the dataset between 1995 and 2011 when aged 15–44 years has
already been generated from the Denmark Chlamydia study.[5] For this analysis the cohort of
516,720 women was limited to women who were tested for chlamydia (n = 286,223). All
women entered the dataset on the date of their first chlamydia test during the study period.
Due to the case-control design of the original Denmark Chlamydia Study we were not able to
obtain a chlamydia prevalence estimate (pe) from the dataset and instead we use the pooled
average estimate from six nationally representative studies of sexually-experienced women
aged 18–26 years (2004–2012).[1] We classified women according to the result of their first
Population excess fraction of chlamydia on pelvic inflammatory disease
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chlamydia test in the cohort and determined the proportion of chlamydia-negative (Iu) and
chlamydia-positive women (Ie) who had a healthcare presentation with PID by 12-months.
For both datasets we used pe, Ie and Iu to calculate: (1) relative risk (RR) of PID in women
who were chlamydia-positive compared to chlamydia-negative at baseline (RR = Ie/Iu); (2)
attributable risk (AR) of chlamydia on PID (AR = Ie-Iu); (3) attributable risk percentage (AR
%) of chlamydia on PID (AR% = [(Ie-Iu)/Ie)]
100); and (4) population excess fraction (PEF) of
chlamydia on PID (PEF = pe(RR-1)/[1+pe(RR-1)]). We then used the PEF to estimate the
number of cases of PID attributable to baseline chlamydia (number of attributable cases = total
cases of PIDPEF) and the number of PID cases attributable to baseline chlamydia per 100,000
women tested for chlamydia (attributable case rate = number of attributable cases/size of
cohort of tested women100,000).
Table 1. Summary of the included studies.
Definitions MWRSH Cohort, Manitoba Canada Denmark Chlamydia Study UK-based POPI-RCT
Design Retrospective cohort of administrative data Retrospective cohort of administrative
data
Randomised controlled trial
Population Manitoba residents Denmark residents Sexually active; non-pregnant; no
chlamydia test <3/12; educational
settings in London
Age 12–24 years in 1992–1996 15–44 years in 1995–2012 16-27 years at recruitment
Entry to cohort First CT test from 1992 onwards at12 years First CT test from 1995 onwards at15
years
Recruitment, 2004–2006
Exit from cohort 31/12/2008; 45th birthday; leaving the
province; death; diagnosis of PID
31/10/2012; 45th birthday; leaving
Denmark; death; diagnosis of PID
12 months
Maximum follow-up 16 years 17 years 1 year
Size 72,883 286,223 2,529
CT test Any non-serological test performed60 days
after a previous test
Genital, rectal or urinary sample30
days after previous test
Vaginal swab self-taken at recruitment
CT positive Positive result at first test in cohort Positive result at first test in cohort Positive result on recruitment sample
CT negative Negative result at first test in cohort Negative result at first test in cohort and
no positive tests during follow-up
Negative result on recruitment sample
CT diagnostic test Chlamydiazyme test~ (1992–98); PACE 2
nucleic acid probe test# or AMP-CT NAAT+
(1999–07); Aptima NAAT^ (2007–08)
Varied across public health laboratories
in Denmark; Change from non-nucleic
acid method to NAATs occurred in
1999/2000
Transcription Mediated Amplification*
CT test
ascertainment
Complete from Cadham Provincial Laboratory Complete from public health
laboratories
Complete from baseline sample
Definition of PID ICD-9 614–616.0; 016.6; 098.10; 098.15;
098.16; 098.17; 098.30; 098.35–7; 099.56;
098.86; ICD-10 N70-74.8; A56.1; A18.1;
A51.4; A54.2; A52.7
ICD-10 A18.2; A51.4; A52.7; A54.2;
A56.1; N70-74.8
Self-reported (or GP for non-
respondents) symptoms of PID;
treatment PID/UTI, laparoscopy or
presentation with abdo/pelvic pain
PID ascertainment Community, out-patient and in-patient Out-patient, ED and in-patient Not stated
Population rate of
gonorrhoea in
women
105 per 100,000 in 2013[10]; 4.2 per 100,000 in 2011[11]; 25.7 per 100,000 in 2012[12]
CT: chlamydia; NAAT: Nucleic Acid Amplification Test; PCR: Polymerase Chain Reaction; ED: Emergency Department
~Abbott Laboratory, Chicago IL
#GenProbe, San Diego CA for urethral /cervical
+GenProbe, San Diego CA for urine
^GenProbe, San Diego CA
*TMA; Gen-Probe, San Diego, CA.
doi:10.1371/journal.pone.0171551.t001
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Systematic review
We conducted a systematic search of Embase, Ovid Medline and Pubmed databases in August
2015 to identify published studies of women in the general population that report the risk of
PID at 12-months in women tested for chlamydia separately by test result (i.e. the risk of PID
in chlamydia-positive and chlamydia-negative women). We searched Pubmed using MESH
terms: "chlamydia", or "Chlamydia trachomatis", or "chlamydia infections" combined with "pel-
vic inflammatory disease", or "reproductive health" and relevant study designs: "cohort studies",
or "follow-up studies", or "observational study", or "randomized controlled trial", or "epidemio-
logic studies", or "case-control studies". We used no date restrictions and limited the results to
human studies published in English (excluding editorials, abstracts and letters in Ovid) where
the full text was available. We adapted this search for Ovid. Studies were eligible if they included:
(1) general population of asymptomatic women; (2) tested for chlamydia at baseline; (3) chla-
mydia-positive and chlamydia-negative women; (4) chlamydia status recorded before PID out-
come; (5) incidence of PID at 12-months by chlamydia test result (positive and negative).
This identified a single eligible study (Fig 1). The Prevention of Pelvic Infection RCT (POPI-
RCT) of Oakeshott et al. recruited 2563 women aged 16–27 years from London-based educa-
tional settings between 2004–2006.[15] Women were randomised to immediate screening and
Fig 1. Flowchart of study selection from systematic review.
doi:10.1371/journal.pone.0171551.g001
Population excess fraction of chlamydia on pelvic inflammatory disease
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treatment (screened-arm) or a deferred testing arm (deferred-arm) where chlamydia samples
were processed at 12-months. This study was performed before chlamydia screening was rolled-
out across England and therefore at the time of the study it was not standard practice to test all
asymptomatic young women for chlamydia. At recruitment all women provided a self-taken vagi-
nal swab and at 12-months 2377 women self-reported (or GP in the case of non-respondents)
PID or symptoms of PID since recruitment. Separately for the screened- and deferred-arms we
extracted pe (defined as the proportion of women who had a positive result on the sample pro-
vided at recruitment), and determined Ie at 12-months. It was not possible to calculate Iu sepa-
rately for each arm, and a combined figure was determined. We used this information to calculate
the RR, AR, AR%, PEF, number of attributable cases, and attributable case rate.
Results
The three studies are from high income countries (Canada, Denmark, and UK). At the time of
the studies, Manitoba and Denmark had widespread chlamydia control interventions includ-
ing testing for asymptomatic people. The UK (England) had not yet implemented chlamydia
screening but widespread testing was undertaken in sexual health clinics (based on risk). The
study populations are 2,529 participants (POPI-RCT), 72,883 (Manitoba) and 286,223 (Den-
mark). The estimated prevalence of chlamydia in women tested for the infection was similar
in Manitoba (5.48% (95% CI 5.31–5.65)) and both arms of POPI-RCT (5.93% (4.63–7.23)
deferred; 5.42% (4.17–6.68) screened)) and lower for the published estimate used for the Den-
mark study (4.3% (3.7–5.0)) (Table 2).
The crude incidence of PID at 12-months in chlamydia-positive women was lowest in Den-
mark (1326/103,334, 1.28% (95% CI 1.21–1.35)), followed by screened-arm of POPI-RCT
Table 2. Summary of risk estimates.
Manitoba,
Canada
Denmark Chlamydia
Study
UK-based POPI-RCT
Deferred
screening
Screened
Prevalence of chlamydia (95% CI) 5.48% (5.31–
5.65)
4.32% (3.65–4.99) 5.93% (4.63–
7.23)
5.42% (4.17–
6.68)
Observed rate of PID per 100,000 women by 12-months 2086.04 890.16 1598.96~ 1346.07~
Incidence of PID in chlamydia positive (95% CI) 5.27% (4.59–
6.00)
1.28% (1.21–1.35) 9.46% (2.79–
16.13)
1.59% (0.00–
8.53)
Incidence of PID in chlamydia-negative (95% CI) 1.90% (1.80–
2.00)
0.67% (0.63–0.71) 1.34% (0.91–1.91)*
Relative risk (95% CI) 2.77 (2.41–3.20) 1.92 (1.78–2.08) 7.06 (3.21–15.55) 1.19 (1.64–
8.55)
Attributable risk 3.37 0.61 8.12 0.25
Attributable risk % 63.95% 48.01% 85.84% 15.63%
Population excess fraction (95% CI) 8.86% (7.15–
10.75)
3.84% (3.26–4.41) 26.44% (11.57–
46.32)
0.99% (0.00–
29.06)
Crude number of cases attributed to baseline chlamydia in cohort
of tested women (study size)
134 (72,883) 98 (286,223) 6 (1270)** 0.1 (1259)**
Number of cases attributed to baseline chlamydia per 100,000
tested women
184 34 484 13
~Data not available to allocate PID incidence in chlamydia-negative women to the two study arms therefore combined chlamydia-negative data used in
calculation
*Data not available to calculate separately
**Assumption that incidence of PID in chlamydia-negative women is 1.34%.
doi:10.1371/journal.pone.0171551.t002
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(1/63, 1.59% (0.00–8.53), Manitoba (210/3991, 5.27% (4.59–6.00)) and deferred-arm of
POPI-RCT (7/74, 9.46% (3.89–18.52)). Chlamydia-negative women had a significantly lower
incidence of PID compared to chlamydia-positive women in all studies apart from the
screened-arm of POPI-RCT. The RR of PID in a chlamydia-positive woman compared to chla-
mydia-negative women ranged from 7.06 (95% CI 3.21–15.55) in deferred-arm of POPI-RCT
to 1.19 (1.64–8.55) in screened-arm of POPI-RCT (Table 2).
At 12-months, the proportion of cases of PID in treated chlamydia-positive women that
could be attributed to a baseline chlamydia infection (AR%) was 15.63% in screened-arm of
POPI-RCT, 48.01% in Denmark and 63.95% in Manitoba. The figure for untreated chlamydia
positive women was 85.84% in deferred-arm of POPI-RCT. The PEF of chlamydia on PID in
the presence of testing and treatment was 8.86% (95% CI 7.15–10.75) in Manitoba, 3.84%
(3.26–4.45) in Denmark and 0.99% (0.00–29.06) in screened-arm of POPI-RCT. In the absence
of treatment the PEF was 26.44% (95% CI 11.57–46.32) in deferred-arm of POPI-RCT. The
PEF of chlamydia on PID in the observational cohorts is between 66.49–85.48% lower than
that in the deferred-arm of POPI-RCT.
If all baseline chlamydia infections had been prevented we estimate that per 100,000
women there would have been 13 fewer cases of PID at 12-months in screened-arm of
POPI-RCT, 34 fewer in Denmark and 184 in Manitoba. If universal treatment was provided in
an untreated setting, we estimate that there would be 484 fewer cases of PID per 100,000 tested
women (deferred-arm of POPI-RCT).
Discussion
Main findings
In the presence of an established testing and treatment programme (Manitoba and Denmark),
less than 10% of diagnosed PID was attributable to baseline treated chlamydia infections. We
found that widespread testing and treatment, as it has occurred in practice, may have reduced
the PEF of chlamydia on PID by at least 65% compared to the untreated setting. The low PEFs
of chlamydia on PID suggest that there are other important causes of PID in all settings and
more information is needed about the aetiology of PID to develop effective strategies for
improving the reproductive health of women.
Strengths and limitations
We have compared the PEF from two settings where widespread chlamydia control interventions
were present (testing and treatment) to the PEFs from the two arms of a RCT: treated and un-
treated infection. Limitations in the analysis of the MWRSH cohort and Denmark Chlamydia
Study are described in full in the original publications.[5, 6] The main limitation is misclassifica-
tion bias in chlamydia and PID status. Chlamydia exposure status was assessed at one time-point
using imperfect diagnostic tests. Therefore the analysis does not capture changes in exposure status
during follow-up (from subsequent diagnosed or undiagnosed infections). The absence of a gold-
standard diagnostic test for PID contributes to a diagnostic bias (misclassification bias) towards
PID in women with a current or past history of infection compared to women with an equivalent
clinical presentation but no documented infection.[16] Under ascertainment of PID diagnoses
due to limitations in the available administrative data also results in a misclassification bias in PID
status. In this analysis, we assume that all diagnosed chlamydia infections were treated.
The systematic literature search was limited to full-text publications in English language
which may have missed potential studies, although these are not known to the authors. The
data available for extraction from the POPI-RCT was not complete and we used a single risk of
PID in chlamydia-negative women across the two arms. The accuracy of our findings will be
Population excess fraction of chlamydia on pelvic inflammatory disease
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affected if this parameter differed. The POPI-RCT was also underpowered to calculate a differ-
ence in the incidence of PID across the two arms.[17]
We were not able to calculate the prevalence of chlamydia in tested women in Denmark
due to the case-control design of the original study and instead used an estimate of population
prevalence from a recent systematic review which may differ from the prevalence in tested
women in the general population.[1, 5]
We used RR to describe the difference in the incidence of PID at 12-months in chlamydia-
positive and -negative women. This measure does not take into account potential loss to fol-
low-up (e.g. outmigration) but given the short duration of the study (12-months) we assume
that loss to follow-up would be low in these large population-based cohorts.
Comparisons of the included studies
The PEF of chlamydia on PID at 12-months varied across the settings with chlamydia testing
and treatment. This variation may be explained by differences in the study populations (e.g.
age range of included women; design of healthcare system), available data (e.g. healthcare set-
tings providing data on PID diagnoses) or unmeasured confounders (e.g. incidence of gonor-
rhoea) rather than an underlying biological difference.
Each study focussed on women of reproductive age, but the age ranges varied (Manitoba
12–24 years at entry; Denmark 15–44 years; POPI-RCT 16–27 years). This is important
because PID-diagnosis rates vary with age (highest in 20–24 year olds) and there are age-
related patterns in the setting of healthcare presentations (younger women (15–24 years) are
more likely to be diagnosed in primary care and older women (25–44 years) are more likely to
be diagnosed in the in-patient setting).[18]
The healthcare systems in the three settings differ in their structure, funding and clinical
pathways. It is possible that women, with an equivalent clinical presentation, would preferen-
tially attend different healthcare facilities in each setting. Further research is needed to explore
the potential impact of this on estimates of PEF. The population-based cohorts contain com-
plete ascertainment of PID diagnoses from the included clinical settings, but these settings var-
ied due to the available data. Ascertainment was likely to be highest in Manitoba (hospital and
primary care events), lower in Denmark (hospital care only) and indeterminate for POPI-RCT
(self-reported). This could impact the PEF as the likelihood that a presentation with PID
occurs in primary care rather than hospital is plausibly related to disease severity (e.g. more
severe disease presenting out of hours in Emergency Departments). This in turn could be
related to the aetiology of the PID as the risk of hospitalisation is higher for Neisseria gonor-
rhoea (gonorrhoea)-associated PID than chlamydia-associated disease.[19]
There are also differences in the rate of gonorrhoea infection in women in the three settings
(Manitoba 105 per 100,000 in 2013[10]; Denmark 4.2 per 100,000 in 2011[11]; UK 25.7 per
100,000 in 2012[12]) and chlamydia-positive women are more likely to be infected with gonor-
rhoea than chlamydia-negative women.[20] Therefore a higher proportion of the PEF of chla-
mydia on PID in Manitoba may be due to unknown co-infection with gonorrhoea and/or a
higher ascertainment of chlamydia-associated PID compared to the other settings.
There are other factors that it was not possible to quantify from the available data that are
likely to contribute to the differences in the observed PEF of chlamydia on PID across the set-
tings. These include the risk profile of women participating with testing (e.g. symptomatic ver-
sus asymptomatic) which may be influenced by clinical practice, treatment rate of diagnosed
infection, performance of interventions designed to prevent re-infection (e.g. partner notifica-
tion; health promotion; widespread testing in men), and diagnostic practices of clinicians that
affect the likelihood that pelvic pain results in diagnosis of PID.[16, 21]
Population excess fraction of chlamydia on pelvic inflammatory disease
PLOS ONE | DOI:10.1371/journal.pone.0171551 February 15, 2017 8 / 12
Comparison with other studies
A recent modelling study has used multi-parameter evidence synthesis to combine data
from multiple sources (including microbiological studies, retrospective case–control studies,
RCTs of screening and routine data).[4] Critical estimates used in this modelling study were
obtained from the POPI-RCT. The authors estimate that the widely used policy of annual chla-
mydia testing in young adults can prevent a maximum of 61% of cases of chlamydia-associated
PID. We analysed the published data from the POPI-RCT and the retrospective population-
based cohorts using a consistent method to improve comparability of the PEF estimates from
each setting. Our findings support the predictions from the modelling study. We found that
widespread testing and treatment, as it has occurred in practice (Manitoba and Denmark),
may have reduced the PEF of chlamydia on PID by at least 65% compared to the untreated set-
ting (POPI-RCT).
Meanings of the study
The low PEF of diagnosed chlamydia on PID suggests that the aetiology of the majority of
diagnosed PID cases is not diagnosed chlamydia. Likely causes include (1) repeat chlamydia
infections after the initial test; (2) infection with another causative agent of PID e.g. gonor-
rhoea or Mycoplasma genitalium; (3) diagnostic bias which tends the differential diagnosis
of pelvic pain towards PID in women with a past history of chlamydia or chlamydia testing.
False negative chlamydia tests at baseline could also explain a small proportion of PID in chla-
mydia-negative women: if we assume a false positive rate of 2% and a risk of progression to
PID for untreated infections of 10% then false negative tests could account for 10% of the
observed PID cases in chlamydia-negative women in Manitoba; 30% in Denmark; and 15% in
POPI-RCT.
The PEF of chlamydia on PID at 12-months varied between settings with testing and treat-
ment. This suggests that population-specific parameters are required for decision making. The
estimate of the PEF from the deferred-arm of the POPI-RCT should be interpreted as a lower
estimate of the potential impact of introducing screening into a naïve population as partici-
pants were “advised to be screened independently”[15] and testing and treatment outside the
study may have occurred. In the settings with widespread control, our study suggests that erad-
icating all diagnosed infections would result in a small reduction in the incidence of PID (up
to 10%). It is possible that expanding interventions may have a further impact on PID by pre-
venting repeat chlamydia infections and infection with other STIs. Mathematical models can
be used to explore these assumptions.
Given the low PEF of chlamydia on PID in the settings with widespread control we suggest
that a renewed focus on the control of PID (and other post-infectious reproductive complica-
tions) should be applied if we wish to improve women’s reproductive health. To achieve this,
better information about the contemporary aetiology of PID is needed in order to ensure that
prevention efforts tackle PID (and other reproductive complications) rather than chlamydia
alone.
Conclusion
Testing and treating chlamydia infections could reduce the PEF of chlamydia on PID by at
least 65%. But in the presence of widespread testing and treatment over 90% of PID cases
within 12-months cannot be attributed to a known baseline chlamydia infection. We require
more information about the contemporary aetiology of PID in order to develop more effective
strategies for improving the reproductive health of women.
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